Research Article
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
Figure 3
(a) Thyroiditis: hyperthyroid phase followed by hypothyroid phase in a patient treated with pembrolizumab. (b) Hyperthyroidism generally occurred within 3–6 weeks of initiation of pembrolizumab therapy (time = 0). Hypothyroid phase was evident by week 9 of pembrolizumab therapy and was characterised by markedly elevated TSH levels.
(a) |
(b) |